Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTEUS: Ranibizumab + PRP for High Risk Proliferative Diabetic Retinopathy
NCT01941329Phase 3Completed
- Sponsor
- AIBILI
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by AIBILI. Primary endpoint: Regression of neovascularization at 12 months. Started Apr 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT01941329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941329.